Andere talen Ribomic Inc.

Aandelen

4591

JP3974850004

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
84 ^JPY	0,00%		-2,33%	-22,22%

13/02	Ribomic Inc. Rapporteert winstresultaten voor de negen maanden eindigend op 31 december 2023	CI
17/01	Ribomic gaat samenwerking aan met Ajinomoto voor geneesmiddelenonderzoek	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	07/03
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	20/02
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	13/02
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	17/01
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	17/01
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	16/01
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	05/12
RIBOMIC Phase I and II Data Published in the Eye	05/12
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	10-08-23
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	10-08-23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12-05-23
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	12-05-23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12-05-23
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	28-04-23
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	10-02-23
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	10-02-23
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	27-12-22
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	23-12-22
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two	29-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ribomic Inc.

Aandelen

4591

JP3974850004

Andere talen

Filters